Tempus AI (NASDAQ:TEM) Now Covered by Analysts at Jefferies Financial Group

Jefferies Financial Group started coverage on shares of Tempus AI (NASDAQ:TEM) in a research report sent to investors on Monday morning, MarketBeat Ratings reports. The firm issued an underperform rating and a $35.00 target price on the stock.

A number of other analysts have also weighed in on the stock. Morgan Stanley cut their target price on shares of Tempus AI from $85.00 to $70.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 3rd. Robert W. Baird initiated coverage on shares of Tempus AI in a research report on Tuesday, February 17th. They issued an “outperform” rating and a $59.00 target price on the stock. Mizuho initiated coverage on shares of Tempus AI in a research report on Thursday, February 19th. They issued an “outperform” rating and a $100.00 target price on the stock. Wall Street Zen lowered shares of Tempus AI from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Finally, Stifel Nicolaus set a $60.00 price target on shares of Tempus AI in a report on Wednesday, February 25th. Nine research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $71.36.

Tempus AI Stock Performance

Shares of Tempus AI stock opened at $45.98 on Monday. Tempus AI has a fifty-two week low of $39.01 and a fifty-two week high of $104.32. The company has a debt-to-equity ratio of 2.52, a current ratio of 3.13 and a quick ratio of 3.00. The firm has a market capitalization of $8.22 billion, a P/E ratio of -32.61 and a beta of 4.90. The company’s 50 day moving average price is $50.85 and its two-hundred day moving average price is $66.55.

Insider Activity at Tempus AI

In other news, EVP Erik Phelps sold 9,464 shares of Tempus AI stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $59.43, for a total transaction of $562,445.52. Following the transaction, the executive vice president owned 79,816 shares in the company, valued at approximately $4,743,464.88. The trade was a 10.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO James William Rogers sold 10,084 shares of Tempus AI stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $59.05, for a total transaction of $595,460.20. Following the transaction, the chief financial officer owned 101,166 shares in the company, valued at approximately $5,973,852.30. This trade represents a 9.06% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 563,841 shares of company stock valued at $32,258,311 in the last quarter. Insiders own 26.27% of the company’s stock.

Hedge Funds Weigh In On Tempus AI

A number of hedge funds have recently bought and sold shares of TEM. GC Wealth Management RIA LLC bought a new position in Tempus AI during the fourth quarter worth $399,267,000. Vanguard Group Inc. raised its stake in Tempus AI by 22.1% during the third quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock worth $762,032,000 after buying an additional 1,706,837 shares during the last quarter. Voloridge Investment Management LLC raised its stake in Tempus AI by 183.0% during the third quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company’s stock worth $129,708,000 after buying an additional 1,039,176 shares during the last quarter. BNP Paribas Financial Markets raised its stake in Tempus AI by 312.7% during the third quarter. BNP Paribas Financial Markets now owns 1,274,549 shares of the company’s stock worth $102,869,000 after buying an additional 965,730 shares during the last quarter. Finally, AQR Capital Management LLC bought a new position in Tempus AI during the second quarter worth $54,020,000. Institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.